Kantum Pharma
Developing groundbreaking therapies and innovative diagnostics to help clinicians prevent and treat acute kidney injury, potentially saving countless lives.
General Information
BounceWatch is an independent company data service, not affiliated with Kantum Pharma. To contact Kantum Pharma, visit kantumpharma.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Kantum Pharma compare?
A PDF of Kantum Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Kantum Pharma soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About Kantum Pharma
Business keywords: acute kidney injury, therapeutics, diagnostics, cardiovascular interventions, critical care, selective receptor antagonist, UDP-G diagnostic test, prophylaxis, clinical studies, ICU settings, sepsis, polytrauma, nephrotoxicity, early diagnosis, patient selection
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | $3.53M | 2 |
|
12 Jul 2021 |
| Venture Round | Undisclosed | 1 |
|
01 Jan 2020 |
| Convertible Note | Undisclosed | 1 |
|
01 Jan 2019 |
Kantum Pharma Alternatives & Competitors
FAQ About Kantum Pharma
Source: BounceWatch company record for Kantum Pharma, https://bouncewatch.com/company/kantum-pharma, updated 27 December 2024. When citing, please name BounceWatch and link this page.
